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Hand Eczema 
 
SUMMARY 
 
 
Hand eczema is a very common and widespread condition, which was 
presumably first described in the 19th century. Due to the high incidence and 
prevalence of this pathology, it has enormous socio-economic consequences. The 
varying degrees of severity also mean that the condition has a massive impact on 
patients’ quality of life. 
This dissertation gives a comprehensive and critical review of current literature and 
studies on the epidemiology, pathogenesis, classification and treatment of chronic 
hand eczema.  
Electronic databases were searched for studies and reports on chronic hand 
eczema.  
This search reveals 16 different treatment modalities of 53 major trials over the last 
40 years. Careful analysis shows that out of the 53 trials, only 8 studies fulfil the 
criteria for a double-blind, randomized control trial, and five out of these eight trials 
use a within patient (left hand, right hand) control. This leaves 3 trials with a clear 
randomization procedure, double-blinding of patients and investigators and separate 
control groups. Thus, a patient population of only 1392 patients in 3 trials is used to 
give evidence for treatment of this very common condition.  
Inadequacies of the trials are discussed in detail, and recommendations are made to 
help to eradicate all shortcomings in the future. 
 
In addition, data from 107 patients suffering from refractory hand eczema, who were 
treated with cream-PUVA photochemotherapy at the Phototherapy Unit at the 
Department of Dermatology, Faculty of Medicine of Heinrich Heine University, 
Düsseldorf, was collected, analysed and also submitted to a peer-reviewed journal as 
a retrospective analysis.  
Complete or partial remission was observed in 78% of treated patients. Patients 
suffering from hyperkeratotic rhagadiform (85%) and from dyshidrotic hand eczema 
(81.1%) received a higher benefit compared to patients suffering from atopic 
(66.67%) or contact hand eczema (20%). 83% of male patients and 72.7% of 
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females showed complete or partial remission. Erythema reactions were reported in 
two patients.  
These results underscore the fact that cream-PUVA photochemotherapy is an 
efficient regimen for the treatment of chronic recalcitrant hand eczema and offers a 
favourable safety profile with respect to acute and long-term side effects. 
Recommendations for a treatment algorithm of chronic hand eczema are made by 
employing the evidence base discussed in this dissertation.  
The significance of regular use of bland emollients and topical corticosteroid is also 
underscored.  
Furthermore UV radiation therapy or treatment with alitretinoin as second line option 
and cyclosporine as third line option is recommended. Use of radiotherapy should be 
advised only for refractory cases. 
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ZUSAMMENFASSUNG 
 
 
Das Handekzem ist ein sehr häufiges und weit verbreitetes Krankheitsbild. 
Vermutlich wurde es zum ersten mal im neunzehnten Jahrhundert beschrieben. Die 
sozioökonomischen Auswirkungen sind enorm, was sich vor allem mit der hohen 
Inzidenz und Prävalenz des Handekzems in der Bevölkerung begründet. Die 
unterschiedliche Schwere der Symptome hat auch gewaltige Auswirkungen auf die 
Lebensqualität des Patienten.  
 
Das Ziel dieser Doktorarbeit ist es, einen umfassenden und kritischen Überblick der 
gegenwärtigen Literatur und wissenschaftlichen Studien zur Epidemiologie, 
Pathogenese, Klassifizierung und Behandlung des chronischen Handekzems zu 
verschaffen. 
Zu diesem Zweck wurden elektronische Datenbanken nach wissenschaftlichen 
Studien und Berichten zum chronischen Handekzem durchsucht. 
Diese Suche ergab 16 unterschiedliche Behandlungsmethoden, die in 53 
wissenschaftlichen Studien der letzten 40 Jahre erwähnt wurden. 
Die sorgfältige Auswertung dieser Studien ergibt, dass nur 8 der 53 Studien die 
Kriterien für doppelblinde randomisierte klinische Studien erfüllen.  
Fünf dieser erwähnten Studien benützen im Halbseitenversuch eine Hand des 
Patienten zur Intervention, während die andere als Kontrolle genutzt wird. Daher 
wurden insgesamt nur drei klinische Studien gefunden, die eine überschaubare 
Methodik zur Randomisierung der Patienten, doppelblinde Patienten und 
Versuchsleiter und separate Kontrollgruppen aufweisen können. 
Dies bedeutet, dass Daten einer Population von nur 1392 Patienten aus drei 
wissenschaftlichen Studien als Grundlage für die Behandlung dieses weit 
verbreiteten Krankheitsbildes angewendet werden können. 
Ferner werden die Unzulänglichkeiten der Studien diskutiert und Empfehlungen 
gemacht, um diese in Zukunft zu vermeiden.  
 
Zusätzlich wurden Patientendaten von 107 Patienten mit refraktärem Handekzem, 
die mit Creme-PUVA-Photochemotherapie in der Lichttherapie-Abteilung in der 
Hautklinik der Heinrich Heine Universität in Düsseldorf behandelt wurden, gesammelt 
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und ausgewertet. Diese Daten wurden schliesslich als Studie bei einer 
wissenschaftlichen Fachzeitschrift eingereicht.  
Vollständiger oder teilweiser Rückgang des Handekzems wurde bei 78% der 
behandelten Patienten bemerkt. Die Therapie bewies sich als wirkungsvoller an 
Patienten mit hyperkeratotisch-rhagadiformem (85%) und dyshidrotischem (81.1%) 
Handekzem als bei Patienten, die unter dem atopischen (66.67%) oder 
Kontaktekzem (20%) litten.  
Vollständiger oder teilweiser Rückgang des Handekzems wurde bei 83% der 
männlichen  und bei 72.7% der weiblichen Patienten bemerkt. Zwei der Patienten 
klagten über Hautrötungen als Nebeneffekt der Bestrahlungstherapie. 
Diese Ergebnisse unterstreichen die Bedeutung von Creme-PUVA-
Photochemotherapie als wirksame Behandlungsmethode von chronischem 
Handekzem. Dies gilt insbesondere für das günstige Sicherheitsprofil in Bezug auf 
kurz- und langfristige Nebenwirkungen. 
Abschliessend wird ein Vorschlag für einen Behandlungs-Algorithmus für das 
chronische Handekzem diskutiert. Hierfür werden die behandelten Studien als 
Grundlage genutzt.  
Die Bedeutung der regelmässigen Anwendung von Emollients und Kortikosteroiden 
sollte betont werden. Der nächste Schritt in der Behandlung sollte UV 
Bestrahlungstherapie oder Alitretinoin sein. Cyclosporine bieten sich als weiterer 
Schritt an, wobei Röntgenbestrahlung nur für behandlungsrefraktäre Fälle 
angewendet werden sollte. 
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Hand Eczema 
 
Introduction and History 
 
 
Robert Willan presumably first reported eczema in 1808, when he described it 
as a prurigo-like condition (Willan, 1808).  
In 1892 Besnier was the first to associate this pathology with hay fever and asthma 
and called the condition prurigo diathésique (Besnier, 1892). 
In 1923 Coca et al. introduced the word atopy, and in 1935 Hill et al. suggested the 
description of atopic dermatitis, which is still used today.  
Fox described an acute blistering disease of palms and soles in 1873, coining the 
word dyshidrosis (Fox, 1873). Three years later in 1876 Hutchinson used the term 
pompholyx to describe a similar condition (Hutchinson, 1876). 
Hand eczema is frequently a manifestation of atopic eczema. It is a distressing 
condition with a high incidence and prevalence. The term, hand eczema, implies that 
the pathology is essentially restricted to the hands and feet with only minor 
involvement of other areas of the body.  
In the following dissertation the specific features, epidemiology, pathogenesis, 
classification and treatment of hand eczema (including eczematous changes of the 
foot) will be explained and discussed in detail. 
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Objectives and Methods 
 
 
The objectives of this work are a comprehensive and critical review of current 
literature and studies on epidemiology, pathogenesis, classification and treatment of 
chronic hand eczema.  
Electronic databases (Cochrane and Pubmed) were searched for studies and reports 
on chronic hand eczema. Table 1 displays terms used for search in the electronic 
databases.  
Table 1 Terms used for search in electronic databases  
 
• Hand eczema 
• Hand dermatitis 
• Foot eczema 
• Foot dermatitis 
• Vesicular palmoplantar eczema 
• Hyperkeratotic hand eczema 
• Recurrent focal palmar peeling 
• Ring eczema 
• ‘Wear and tear’ dermatitis 
• Fingertip eczema 
• Apron eczema 
• Discoid/nummular eczema 
• Chronic acral dermatitis 
• Eczema craquelé 
 
Studies from 1956 to 2007 are reported here. Randomized and non-randomized 
studies were considered while case reports and reviews were excluded.   
In addition for the purpose of this dissertation data from 107 patients suffering from 
refractory hand eczema, who were treated with cream-PUVA photochemotherapy at 
the Phototherapy Unit at the Department of Dermatology, Faculty of Medicine of 
Heinrich Heine University, Düsseldorf, was analysed by the author of this dissertation 
and subsequently submitted to a peer-reviewed journal as a retrospective analysis.  
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Hand Eczema 
 
3.1 Epidemiology 
 
Hand eczema is a very common condition and a widespread phenomenon. The 
prevalence and incidence can only be estimated in a population, as many affected 
will never consult a medical practitioner.  
There is no universal classification for hand eczema and different morphological 
types of eczema respond to the same treatment modalities. Hence studies and 
reports regarding hand eczema are described together. 
Elston et al. (2002) state that 2% to 10% of the general population is suffering 
from hand eczema. Agrup (1969) states that 2% of the population of a county in 
South Sweden were affected by hand eczema, out of which 25% had consulted a 
doctor in the previous year. One quarter had never seen a doctor for their symptoms. 
Point prevalence of atopic eczema in Great Britain and Scandinavian countries lies 
between 9.7% and 23% (Rothe et al. 1996; Wüthrich 1996). In addition 20% to 35% 
of all dermatitis will involve the hands (Elston et al. 2002). A European survey of 
4000 cases showed that hand eczema accounted for 30% of cases of eczema 
(Ekelund and Möller 1969). 
 
Hand eczema is more common in certain populations. Women are affected twice as 
commonly as men (Meding and Swanbeck 1989). The same authors found the 
highest prevalence among service workers and women in a study in Gotheburg, 
Sweden (Meding and Swanbeck 1990). In an English study Smith et al. (2000) 
investigated 6849 patients attending a contact dermatitis clinic in London over a 
period of 15 years. In this study men were more commonly affected. 25% of patients 
with dermatitis had hand dermatitis. 
 
Eczema of the hands also seems to be more common in younger patients. The 
Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis investigated 
the prevalence of hand eczema in adolescents in a cross sectional study using a 
questionnaire, interview, clinical examination and patch testing. The lifetime 
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prevalence of hand eczema was 9.2%. The 1-year period prevalence and the point 
prevalence were 3.2% (Mortz et al. 2001).  
In a 4-year-study in a population of 4055 in North America, Nethercott et al. (1991) 
investigated age and sex using a patch testing routine. They report hand dermatitis in 
almost half of the study participants (43.5%) and an increased frequency among the 
cohort of patients younger than 40 years of age. The same authors compared non-
occupational with occupational dermatitis using the same testing routine in a 
population of 1579. They state that 82.6% of subjects with occupational dermatitis 
had hand dermatitis. 
 
Hand eczema appears to be the most common occupational skin disease with a 
prevalence of 9% to 35% (Elston et al. 2002) affecting various occupations to a 
different degree. 
In a retrospective cohort study in the Netherlands, the incidence of hand dermatitis 
was investigated. A cohort of 371 nurses and 110 office employees was considered 
in this study. It was estimated that the overall incidence among nurses was 6.5 
cases/1000 person-months. This is compared to an incidence of 1 case/1000 person-
months among office employees (Smith and Coenraads 1993). In a survey study six 
different occupations were compared by Smit et al. (1993). The study revealed 
highest prevalence in females and nurses. Other occupations that are commonly 
affected include food handlers, hairdressers and construction workers (Elston et al. 
2002).  
A German study followed 2352 hairdressing apprentices for 3 years by three 
examinations and found an increase in point prevalence of irritant skin changes of 
the hands from an initial value of 35.4% to 55.1% in the final examination (Uter et al. 
1998).  
 
3.2 Socio-economic considerations 
 
As mentioned previously it is estimated that 2% to 10% of the general 
population is suffering from hand eczema (Elston et al. 2002). Therefore, at any one 
point in time, a very large proportion of a population is suffering from the 
 - 15 -
Hand Eczema 
 
consequences of this disease. The consequences on quality of life and the socio-
economic cost are hence considerable.  
Fowler et al. (2006) investigated the impact of chronic hand eczema on quality of life, 
work productivity, activity impairment and medical costs in a population of 507 
members of a Massachusetts managed care organization. To do this they used 
questionnaires. The authors report a significantly reduced quality of life score, work 
productivity and activity impairment in patients with chronic hand eczema. In addition 
a 25% increase in total medical costs was attributed to the effects of chronic hand 
eczema. No significant difference in work time missed has been reported.  
In a Swedish study, Meding (1990) states that among a cohort of patients with hand 
eczema, 8% changed their jobs and 21% had been on sick leave at least once. 81% 
of the patients reported some degree of impairment in their daily life related to their 
condition. 
Cvetkovski et al. (2006) report a prevalence of 9% of moderate to severe depression 
based on a study which looked at quality of life and depression in a population of 
occupational hand eczema patients. 
Meding et al. (2005) investigated persistence and consequences of hand eczema in 
a fifteen-year follow-up with a cohort of 868 patients. 3% reported a change to 
another occupation because of their hand eczema. About 5% reported long sick-
leave periods and sick pension. 
Burnett et al. (1993) state that, according to data collected from the Bureau of Labor 
Statistics in the United States of America regarding specific occupations, 14% of 
those affected by hand eczema stayed away from work for more than 10 days. 6.6% 
lost more than 20 workdays. 
 
3.3 Pathogenesis of atopic eczema 
 
Hand eczema is thought to be the result of several factors in complex 
interaction with each other. Idiopathic, immunological or psychosomatic factors and 
dyshidrosis are important endogenous causes. Exogenous reasons such as contact 
allergens, ingested allergens or infections are significant as well.  
 - 16 -
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There is no universal classification for hand eczema and different morphological 
types of eczema respond to the same treatment modalities. Hence studies and 
reports regarding hand eczema are described together. 
Eczema is characterised by infiltration of T-lymphocytes, monocytes and 
macrophages into the skin lesion (Hanifin and Rajka. 1980). 
Genetic factors play an important role in the development of eczema in general.  
Uehara and Kimura (1993) studied 270 adults with atopic eczema and found that 
60% of their subjects' offspring were affected. The prevalence varied from 81% when 
both parents had atopic eczema to 59% when one parent had atopic eczema.  
Schultz Larsen's (1993) investigation of twins discovered that monozygotic twins are 
more often concordant for atopic dermatitis than dizygotic twins. 
Saurat (1985) investigated patients with Wiskott-Aldrich syndrome, who classically 
present with thrombocytopenia, small platelets, eczema, and immunodeficiency. He 
found that the patients’ skin rash could be cleared after bone marrow transplantation. 
This suggests involvement of a bone marrow derived cell in the pathogenesis of 
eczema.     
Leung (1992) suggests another mechanism. He claims that immune activation, 
resulting in chronic atopic eczema, may be the consequence of an underlying T cell 
defect. This causes decreased IFN- gamma production and an increased number of 
Th2 cells producing IL-4 and IL-5. He states that this leads to an increased IgE 
production, eosinophilia and mast cell number in addition to increased expression of 
the CD23 low-affinity IgE receptor on mononuclear cells. Ruzicka et al. (1991) also 
refer to an enhanced releasability of histamines, leukotrienes and other inflammatory 
mediators contributing to the inflammatory reaction in the skin and decreased cellular 
immunity.  
Hamid et al. (1994) present similar data and show that acute and chronic atopic 
eczema lesions are associated with increased levels of IL-4 and IL-5. They state, 
however, that the initiation of acute skin inflammation is associated with a 
predominance of IL-4 expression and chronic inflammation with increased IL-5 
expression and eosinophil infiltration. 
Immunoglobulins E have a key role in the development of atopic eczema. The 
presence of IgE molecules on epidermal Langerhans cells, which seems to be 
specific for patients with atopic eczema, was shown by Bruijnzeel-Koomen et al. 
(1986) using anti-human IgE antibodies and the indirect immunoperoxidase 
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technique. It has to be stated, however, that in approximately 20 percent of patients 
with atopy normal total serum levels of IgE and negative IgE and prick test results 
can be found. In addition high levels of IgE can be found in patients with no clinical 
evidence of eczema or atopy (Ruzicka, 1998).   
Mao et al. (1996) report a genetic association between variants of mast-cell 
chymase, a serine protease secreted by skin mast cells, and atopic eczema. They 
suggested variants of chymase might be one source of genetic risk for eczema. 
 
The previously mentioned cellular immune deficiency found in atopy is also the cause 
of an increase in muco-cutaneous infections. Ruzicka and Geltinger (1995) 
investigated fifty-eight patients with condylomata acuminata and found a positive 
association between the atopy score and relapse rate of condylomata acuminata. 
They suggested the presence of atopy is a predisposing factor for human 
papillomaviruses infection. Infections with other viruses such as herpes simplex or 
bacteria such as staphylococci (Hanifin and Homburger, 1986) or fungi are common 
as well (Ruzicka, 1998).  
Staphylococcus aureus can be found in 90% of atopic eczema skin lesions. Normally 
about 5% of normal subjects will carry staphylococcus aureus on their skin (Leung, 
2000). This bacterium secretes superantigens such as enterotoxin A and B and toxic-
shock syndrome toxin 1 (Breuer et al. 2000 and Leung et al. 1993). 
 
A disturbance in the epidermal lipid metabolism leading to a disruption of the skin 
barrier is another pathophysiological factor that can result in increased irritability of 
the skin. A deficiency in delta-6-desaturase has been postulated (Melnik and Plewig, 
1989; Ruzicka, 1998). Rajka (1974) compared transepidermal water loss on the 
hands in 14 patients with atopic dermatitis and controls and found a significant 
increase in atopic dermatitis.  This gives evidence for a qualitative change in the 
lipids of the skin. 
Palmer et al. (2006) studied loss-of-function variants of the epidermal barrier protein 
filaggrin. Filaggrin is a key protein facilitating terminal differentiation of the epidermis 
and is involved in formation of the skin barrier. They show that two loss-of-function 
variants are very strong predisposing factors in the formation of atopic eczema. This 
underscores the role of impaired skin barrier function in the development of atopic 
eczema. 
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Cork et al. (2006) claim that skin may be impaired by a genetic predisposition, which 
leads to increased levels of stratum corneum chymotryptic enzyme, thus causing 
premature breakdown of corneodesmosomes. This can lead to skin barrier 
dysfunction. 
 
An autonomic dysregulation has also been postulated by Hanifin (1984) resulting in 
an imbalance between the beta-adrenergic receptors of the sympathetic and the 
cholinergic receptors of the parasympathetic nervous system. This can again result in 
an increased release of inflammatory and immunoregulatory mediators from 
leukocytes or mast cells.  
 
Atopic eczema may worsen with anxiety or stress. This has been associated with 
anomalous neuropeptide regulation (Sirinek and O'Dorisio, 1991). Using three 
functional assays, Hosoi et al. (1993) showed that calcitonin gene-related peptide 
inhibited Langerhans cell antigen presentation. This gives evidence for 
immunomodulatory effects of calcitonin gene-related peptide in vivo and suggests an 
interaction between the nervous system and immunological function. 
 
Grewe et al. (1998) describe a model of sequential T cell activation in the 
pathogenesis of atopic eczema. The authors propose a genetic predisposition 
resulting in an imbalance of the immune system. This causes the differentiation of 
Th2-type immunological characteristics. The increased number of Th2 cells releasing 
cytokines, the enhanced IgE levels and blood eosinophilia are all involved in the early 
stages. The cytokines released by Th2 cells activate macrophages and attract 
eosinophils. IL-12 released by those two cells then causes activation of allergen-
specific and non-specific Th1 and Th0 cells. In the late process it is the higher 
proportion of IFN-γ-producing T cells that drives the chronic phase of atopic eczema. 
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Fig 1 Model for pathogenesis of eczema. 
 
Grewe et al. (1998) propose a genetic predisposition resulting in an imbalance of the immune system. 
Initially this causes the differentiation of Th2-type immunological characteristics. The cytokines 
released by Th2 cells activate macrophages and attract eosinophils. IL-12 released by those two cells 
then causes activation of allergen-specific and non-specific Th1 and Th0 cells. In the late process it is 
the higher proportion of IFN-γ-producing T cells that drives the chronic phase of atopic eczema. 
Homey et al. (2006) suggest another mechanism, an amplification cycle of atopic 
skin inflammation, which starts with pruritus. Subsequent scratching induces 
mechanical injury and leads to proinflammatory cytokine (IL-1, IL-18, TNF-α, and 
GM-CSF) and chemokine (CCL27) production. This results in recruitment of 
pathogenic leukocytes to the skin (Homey et al. 2002). As a common feature, 
leukocyte activation results in the release of inflammatory mediators such as effector 
cytokines (IL-31) and proteases (tryptase). Together with neuropeptides those factors 
perpetuate pruritic signals (Dillon et al. 2004 and Steinhoff et al. 2003). This cycle 
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can sustain the inflammatory response within the skin and could lead to the 
development of an eczema phenotype.  
Fig 2 Model for pathogenesis of eczema. 
 
Homey et al. (2006) propose an amplification cycle of atopic skin inflammation, which starts with 
pruritus. Scratching induces mechanical injury and leads to proinflammatory cytokine and chemokine 
production. This results in recruitment of pathogenic leukocytes to the skin. Th2 cells suppress the 
production of antimicrobial peptides. Increased release of inflammatory mediators, including effector 
cytokines (IL-31) and proteases (tryptase), perpetuate pruritic signals. 
 
3.4 Signs and Symptoms 
 
The different subtypes of hand eczema have their own unique features. These 
will be described in detail in due course. The general features are considered here. 
Acute eczema is characterised by exudation, crusting and blistering of the skin. Ill-
demarcated erythema with papules and oedema is common. The same is true for 
scaling. Vesicles are not umbilicated. 
Chronic eczema is a less vesicular and exudative state and is characterised by more 
scaly, pigmented and thickened skin. In addition, lichenification, a leathery thickened 
state secondary to repeated scratching, is also found. Lichenification is characterised 
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by thickening of the epidermis with deepening of the skin lines in either a parallel or a 
rhomboidal pattern. 
Fissures, which can be very painful, are another feature of chronic eczema (Hunter et 
al. 2002). 
Itching and pain are the principal symptoms. 
 
Secondary infection with viruses, e.g. herpes (eczema herpeticum), or bacteria, e.g. 
staphylococci (Hanifin and Homburger, 1986) is a very common phenomenon 
leading to exacerbation of the symptoms.   
 
3.5 Classification 
3.5.1 Aetiological Classification 
 
As mentioned previously most cases of hand eczema are multifactorial. Many 
separate factors can cause hand eczema while several different aetiologies may 
interact with each other.  
 
3.5.1.1 Exogenous Causes 
3.5.1.1.1 Contact allergens and irritants 
 
The most common cause of hand eczema is contact eczema (Meding and 
Swanbeck, 1989). It can be further subdivided into irritant or allergic contact eczema 
(Elston et al.  2002).  
Due to the disturbance in the epidermal lipid layer, the skin barrier is disrupted. This 
makes it easier for contact allergens and irritants to penetrate the skin (Ruzicka, 
1998). 
As mentioned in the section on epidemiology, hand eczema appears to be the most 
common occupational skin disease with a prevalence of 9% to 35% (Elston et al. 
2002). 
Jappe et al. (1999) investigated garlic-related dermatoses in food handlers using a 
type-IV patch test reaction. They point out that diallyl disulfide, a low molecular 
weight garlic ingredient can cause irritant contact dermatitis, protein contact 
dermatitis and allergic contact dermatitis.  
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Incidence of hand eczema also increased from 3.3% to 27% in baker and 
confectioner apprentices after 12 months of training (Bauer et al. 1998). 
Hairdressers and construction workers appear to be frequently affected as well. 
Majoie et al. (1996) followed a group of junior hairdressers over a period of 8 years. 
51% of this cohort had hand eczema after this time period, even though no subject 
was affected at the start of the study. Common contact irritants for this occupation 
appear to be glyceryl monothioglycolate and ammonium persulfate (Leino et al. 
1998).  
Fischer et al. (1995) found that 25 of 202 house painters using water-based paints, 
glues and putties had hand eczema. Commonly identified allergens were nickel and 
cobalt, colophony, isothiazolinones and p-tert-butyl-phenol formaldehyde. 
Epoxy resin systems were identified as sensitizers in 44 of 511 workers in aircraft 
manufacture (Hackett 1999) and cow dander was identified as a sentitizer in Finish 
farmers with hand eczema (Susitaival et al. 1995). 
Nickel (Kanerva et al. 1997) and rubber are two well-investigated contact allergens. 
De Groot (1998) investigated the prevalence of natural rubber latex allergies in 
laboratory workers in the Netherlands. He states that 28 out of 98 workers had glove-
related symptoms. Positive patch testing was found in 6.6%.  
Holness and Nethercott (1997) performed patch testing with 47 agents in 235 
patients with a specialized collection of plastic and glue components. 13% had a 
positive response to at least one of the allergens. 74% were relevant to either the 
present or a past problem, and 64% were occupationally related.  
The list of other contact allergens is substantial. Some other common allergens are 
acrylates (Bruze et al. 1995), metalworking fluids (Elsner et al. 1995), laboratory 
chemicals (Sasseville et al. 1996) and medication (Filipe et al. 1996). 
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Table 2 Common contact allergens in chronic hand eczema (Elston et al. 2002) 
 
• Soaps 
• Detergents and cleansers 
• Metals and metallic salts (nickel) 
• Plastics 
• Resins 
• Plant allergens 
• Organic dyes 
• Rubber and latex 
• Preservatives 
• Acrylates 
• Metalworking fluids 
• Laboratory chemicals 
• Medication 
 
3.5.1.1.2 Inhaled or Ingested allergens 
 
Inhalant allergens can also penetrate the skin and cause allergic reactions. 
This can explain the seasonal variation in severity of eczema symptoms depending 
on the pollen count (Ruzicka, 1998).  
Another very important allergen stems from house dust mites. The epidermal barrier 
can be damaged by exogenous proteases from house dust mites and staphylococci. 
This can intensify allergen penetration and cause inflammatory reaction, thus 
contributing to exacerbations of eczema (Cork et al. 2006).  
Tan et al. (1996) have shown in a double-blind, placebo-controlled study that the 
activity of atopic dermatitis can be greatly reduced by effective house dust mite 
avoidance. They did this by actively reducing house dust mite exposure in the 
treatment group.   
 
Ingestion of allergens has been postulated to provoke or exacerbate hand eczema. A 
study was performed in 12 female patients with contact allergy to nickel and hand 
eczema. Intense handling of nickel-contaminated metal objects did not cause any 
visible eczematous activity. Nickel was then administered orally in a double-blind 
test. This provoked an aggravation of the hand eczema in nine of the twelve patients 
(Christensen and Möller 1975).  
Christensen (1982) then found that oral administration of disulfiram tablets cleared 
eczema in three patients with severe nickel contact dermatitis. 
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Veien et al. (1985) report a similar finding. An oral provocation test with balsam of 
Peru was carried out in 221 patients with various types of dermatitis. 21% of the 
patients had a flare-up of their symptoms.  
 
3.5.1.1.3 Infection 
 
As mentioned in the paragraph above, the epidermal barrier can be damaged 
by exogenous proteases from staphylococcus aureus, decreasing the skin’s ability to 
act as a barrier. This can intensify allergen penetration and cause inflammatory 
reactions, thus contributing to exacerbations of eczema (Cork et al. 2006). 
Secondary infections with viruses such as herpes simplex or bacteria such as 
staphylococci (Hanifin and Homburger, 1986) or fungi are commonly found in atopic 
eczema as well (Ruzicka, 1998). Therefore, it can not only be assumed that atopy is 
a predisposing factor for infection but also that infections can contribute to 
exacerbation and development of hand eczema. The role of staphylococcus aureus 
has been discussed in the chapter on pathogenesis of acute eczema. 
 
3.5.1.2 Endogenous 
 
Idiopathic, immunological, psychosomatic factors as well as dyshidrosis play 
an important part in the aetiology of hand eczema. Patients with atopy, i.e., patients 
with hay fever, allergic rhinitis or asthma, are more likely to develop eczema. Atopy 
accounts for the most common cause of endogenous eczema (Epstein 1984). Hand 
eczema is more common in patients with a history of eczema in general. In addition 
20% to 35% of all dermatitis will involve the hands (Elston et al.  2002).  
Lodi et al. (1992) investigated 104 patients with pompholyx. They found familial and 
personal atopic diathesis in 50% of patient versus 11.5% of controls. Hyperhidrosis 
was claimed by 38 of the patients to be an exacerbating factor. 
Evidence for psychosomatic influence in the development of eczema has been given 
before. Anxiety or stress may worsen eczema. This has been associated with 
anomalous neuropeptide regulation (Sirinek and O'Dorisio, 1991), which can affect 
lymphocyte function. Niemeier et al. (2002) have investigated psychological factors 
associated with hand dermatoses. In a cross-sectional study 101 hand dermatosis 
patients including 33 with vesicular hand eczema and 42 with contact dermatitis were 
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examined. Dermatological, allergological and psychological aspects were 
considered. 47.52% were convinced that stress could influence the course of their 
disease.  
3.5.2 Morphological Classification 
 
A variety of patterns of hand eczema differing in symptoms and severity have 
been described in the literature. In the following paragraphs, the most common will 
be discussed.  
Table 3 Morphological types of hand eczema 
 
• Vesicular palmoplantar eczema 
• Hyperkeratotic hand eczema 
• Recurrent focal palmar peeling 
• Ring eczema 
• ‘Wear and tear’ dermatitis 
• Fingertip eczema 
• Apron eczema 
• Discoid/nummular eczema 
• Chronic acral dermatitis 
• Eczema craquelé 
 
3.5.2.1 Vesicular palmoplantar eczema 
 
Vesicular Palmoplantar eczema can be divided into three categories: 
pompholyx, chronic vesiculobullous hand eczema and id reactions. Chronic 
vesiculobullous hand eczema is also called dyshidrotic hand eczema (Rook et al. 
1998). 
Pompholyx is confined to palms and soles of affected individuals. It is characterised 
by eczematous changes in which fluid accumulates to form vesicles or bullae. 
Depending on the site of occurrence pompholyx is either called cheiropompholyx 
(palms) or podopompholyx (soles) (Rook et al. 1998).  
Pompholyx is characterised by an acute explosive outbreak of vesicles and bullae. 
There is no erythema, but a sensation of discomfort and itching may precede the 
onset of the outbreak. Blisters can coalesce and desiccate and resolve without 
rupture (Fitzpatrick 2003). It is associated with stress and has an increased 
occurrence during the spring and fall. 
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Fig 3 Hand of a patient with dyshidrotic hand eczema 
 
Hand of a patient with dyshidrotic hand eczema. Scaling, thickening, and painful fissures typically 
occur subsequent to vesicles. 
 
Fig 4 Hand of a patient with dyshidrotic hand eczema 
 
Hand of a patient with dyshidrotic hand eczema. Vesicles predominate. 
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Pompholyx is more common in patients between 10-40 years of age. Outbreaks 
terminate spontaneously and resolution will take place within 2 to 3 weeks. If attacks 
recur, spread to the dorsum of the fingers can occur and dystrophic nail changes 
might be found. Recurrences are typical in intervals of 3-4 weeks. (Rook et al. 1998).    
 
Fig 5 Hand of a patient with chronic hand eczema 
 
Hand of a patient with chronic hand eczema. Dystrophic nail changes are visible. 
 
 
Agrup (1969) states that pompholyx accounts for about 6% of hand eczema cases. In 
80% of cases only the hands will be involved, while hands and feet or feet alone will 
be affected in about 10% of patients. (Rook et al. 1998).  
Smaller vesicles (1-2mm) on the inner aspect of the fingers or palms signify chronic 
vesiculobullous hand eczema. This type is more common and is characterised by a 
relapsing course (Fitzpatrick 2003).  
Inflammatory reactions, especially fungal infections anywhere on the body, can 
produce an id reaction. This is characterised by pruritic vesicles and bullae on the 
lateral aspect of the fingers. The symptoms resolve with treatment of the underlying 
condition (Fitzpatrick 2003). 
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These types of hand eczema are mostly caused by endogenous factors. Yokozeki et 
al. (1992) identified hyperhidrosis as an exacerbating factor. They found that the 
perspiration volume in patients with pompholyx was 2.5 times higher than that of 
controls. Miller and Coger (1979) investigated 33 patients with dyshidrotic eczema. 
The subjects were trained to modify the electrical conductivity of their skin. Subjects 
trained to decrease skin conductance showed clinical improvement more often than 
the controls.  
Some studies have proposed a hereditary predisposition to pompholyx. Lorincz and 
Grauer (1956) have reported simultaneous dyshidrosis in monozygotic twins during 
their separation.  
As discussed above, primary irritants, contact allergens and ingested metals can 
cause and exacerbate hand eczema. Christensen and Möller (1975) performed a 
study in 66 patients with hand eczema and contact allergy to nickel. The clinical 
examination found pompholyx in 77 % of cases.  
 
 
Fig 6 Patient with contact eczema to nickel in jeans stud 
 
Patient with contact eczema to nickel in jeans stud. 
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Fig 7 Patient with contact eczema to material on sandals 
 
Patient with contact eczema to material on sandals. 
 
 
 
 
 
 
 
3.5.2.2 Hyperkeratotic hand eczema 
 
Hyperkeratotic hand eczema is less vesicular in the clinical presentation than 
vesicular palmoplantar eczema and tends to be confined to the centre of the palms. 
Hyperkeratotic plaques and fissures can be found. The skin is irritable and scaly. 
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Fig 8 Patient with hyperkeratotic hand eczema 
 
Patient with hyperkeratotic hand eczema. The skin is scaly and dry, and infiltrated plaques and 
fissures are visible on the palmar surface. 
 
Fig 9 Patient with hyperkeratotic foot eczema 
 
Patient with hyperkeratotic foot eczema. Dry and infiltrated, scaly plaques and deep painful fissures 
are visible on the plantar surface. 
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It is more common in men and in older age groups and is very refractory to treatment 
(Rook et al. 1998). In one study 32 adult patients with hyperkeratotic eczema were 
re-examined 10 years after the first presentation. Topical treatments did not cause 
much improvement, and symptomatology was unchanged in 30 of the patients 
(Hersle and Mobacken 1982). Mobacken et al. (1983) however reported 
improvement in five patients with chronic hyperkeratotic dermatitis of the palms after 
using oral psoralen photochemotherapy (PUVA) (Hersle and Mobacken 1983). 
According to Rook et al. (1998) 2-5% of applications for permanent disability 
pensions in Western Europe are due to this condition. 
Patch tests tend to be negative in this pattern, and the incidence of atopy is not 
increased as compared to controls (Rook et al. 1998). 
 
3.5.2.3 Recurrent focal palmar peeling 
 
Another name for this condition is keratolysis exfoliativa. It is widely held that 
this condition might represent a mild form of pompholyx. It is a chronic non-
inflammatory condition. Small areas of white desquamation develop superficially on 
the sides of the fingers, palms or feet. Scaling commonly begins on one or two pin-
sized white spots and enlarges outward into circular areas producing a collarette of 
scale (Fitzpatrick 2003). The palms are more frequently affected than the soles (Kalia 
and Adams 2005). The onset is sudden and expansion of the lesion is common 
before self-limited resolution. Some patients might go on to develop pompholyx. 
Recurrent focal palmar peeling is more common in hot climates, especially during the 
summer (Rook et al. 1998). 
 
3.5.2.4 Ring eczema 
 
This pattern of hand eczema is presumably due to soap or detergent 
accumulation beneath rings in addition to microtrauma. It presents classically in 
young women after marriage or childbirth. Patients complain of a patch of eczema 
under a ring typically involving adjacent areas on neighbouring fingers and the palm. 
Sometimes more diffuse eczema can arise. Sensitivity to metals such as gold or 
copper cannot be proven (Rook et al. 1998). 
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3.5.2.5 ‘Wear and tear’ dermatitis 
 
‘Wear and tear’ dermatitis is also called asteatotic hand eczema, housewives 
dermatitis, dry palmar eczema or dermatitis palmaris sicca. 
As implied by the name, it commonly affects in housewives and cleaners. 
Presumably the skin is irritated by soap and mild trauma due to cleaning and 
asteatosis.  
Patients complain of dry, erythematous skin with white superficial fissures and cracks 
due to damage of the horny layer. Small vesicles are found, appearing like “tapioca” 
in clusters (Fitzpatrick et al. 2001). This leads to decreased elasticity of the skin. The 
palms are affected together with the dorsa of the knuckle joints.  
Some patients with juvenile plantar dermatosis have hand involvement. It is then 
called dermatitis palmaris sicca (Rook et al. 1998). 
 
3.5.2.6 Fingertip eczema 
 
This condition presents in two patterns. Both patterns present with dry, 
cracked and fissured skin on the palmar surfaces of the fingers. 
It either involves all the fingers, especially on the dominant hand, or is confined to the 
thumb, forefinger and third finger of the master hand. The former is a cumulative 
irritant dermatitis in which irritant agents combine with constant trauma. This is one 
reason why the symptoms improve during a holiday.  
The latter can be caused by irritation or allergy. Gette and Marks (1990) report an 
allergic contact dermatitis from handling tulip bulbs in workers in the tulip industry. 
This was confirmed by positive patch test reaction to pieces of tulip bulbs and to 
tuliposide A, an allergen in tulips.  
 
3.5.2.7 Apron eczema 
 
Cronin (1985) studied hand eczema of 263 women and found that a palmar 
pattern was the most common. The pattern of hand eczema involving the proximal 
palmar aspect of two or more fingers and the neighbouring palmar skin over the 
metacarpophalangeal joints was coined apron eczema. This pattern was practically 
always secondary to endogenous causes. 
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3.5.2.8 Discoid / nummular eczema 
 
Discoid or nummular eczema is signified by coin-shaped, circular or oval 
lesions with a well-defined border. This pattern of eczema is more frequent in the 
male gender with a peak in the age of onset at around 60 years of age. In women the 
incidence can peak around 20 years of age.  
The outbreak is characterised by vesicles and papules. A lesion may coalesce to a 
size of about 10cm. The plaques have an erythematous base with distinct borders. 
Oedema and exudation is present and pruritus and burning can occur.  
This pattern is most commonly seen on the legs or dorsal surfaces of the hands 
(Fitzpatrick 2003). IgE levels are normal (Fitzpatrick et al. 2001). 
Ayoama et al. (1999) investigated patients with nummular eczema. They report a 
higher percentage of positive patch test reactions to dermatophagoides farinae 
allergen, house dust allergen and candida albicans. In addition, they assessed the 
stratum corneum of the patients and found a significantly lower hydration state. 
 
3.5.2.9 Chronic acral dermatitis 
 
Chronic acral dermatitis is a syndrome characterised by hyperkeratotic 
papulovesicular lesions of the hands and feet. Pruritus is the main symptom.  
There is no history of atopy but IgE levels are extremely elevated (Winkelman and 
Gleich 1973 and Rook et al. 1998).  
 
3.5.2.10 Gut eczema 
This pattern of hand eczema has also been called slaughterhouse eczema. It 
is occurs in workers working with and cleansing gut casings. Characteristically, the 
eczema starts in vesicles in the web spaces of the fingers spreads in the sides of the 
fingers. It is a self-limiting condition that recurs frequently in monthly or yearly 
intervals. Prick tests with extracts of ascaris and several organs of the pigs were 
negative (Hjorth 1978). 
Goranson (1982) reported occupational contact urticaria to fresh cow and pig blood 
in slaughtermen.  
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3.5.2.11 Eczema craquelé 
Eczema craquelé, also called asteatotic eczema, is seen in elderly patients. It 
is usually found on the legs but can also occur on the arms or abdomen. A crazy-
paving pattern develops (Graham-Brown and Burns, 2002) with pruritic, dry, cracked 
polygonally fissured skin. Treatment with emollients is sometimes sufficient, but mild 
steroid ointment might become necessary. 
3.6 Differential Diagnosis 
 
Psoriasis should always be considered in the differential diagnosis, especially 
pustular psoriasis in the diagnosis of pompholyx (Rook et al. 1998). The rash tends 
to be more sharply demarcated and occurs with a silvery scale as compared to 
eczema, and generalised involvement is common. Pruritus is also less of a symptom 
in psoriasis. Nail pitting and transverse ridging can be a helpful feature in the 
distinction of the two pathologies. 
Fig 10 Hand of a patient with psoriasis pustulosa 
 
Figure 10.  Hand of a patient with psoriasis pustulosa. A sharply demarcated, erythematous area with 
pustules and a silvery scale is visible especially over the hypothenar eminence. 
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Scabies, lichen planus and fungal infection (e.g. Trichophyton or Trichosporon) 
(Nakagawa et al. 2000) can mimic some features of hand eczema.  
Lichen planus presents with lesions on the oral mucosa and has a violaceous tinge. 
The lesions are shiny flat topped papules. 
 
 
 
 
Fig 11 Hands of a patient with lichen planus 
 
Hands of a patient with lichen planus. Papules imitating dyshidrosis are visible over both palms with 
typical polygonal papules over both wrists. 
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Fig 12 Hand and feet of a patient with trichophyton rubrum 
 
 
A. Hand of a patient with trichophyton rubrum. B. The focus can be found on examination of the 
patient’s feet showing onychomycosis.  
 
In scabies, burrows can be found, genitals and nipples may be involved and contacts 
tend to be affected as well.  
Fungal infections are annular lesions with active scaly edges (Hunter et al. 2002). 
Dermatophytosis can also present as a circumscribed and asymmetrical area with 
scaling and vesiculation (Rook et al. 1998).  
Pemphigoid can sometimes present with large blisters on the hands and look similar 
to pompholyx (Duhra and Ryatt, 1988). 
Other chronic dermatoses such as ichthyoses, malignancies such as cutaneous T 
cell lymphoma, and immunologic disorders such as dermatitis herpetiformis or 
dermatomyositis have to be considered as well.  
 - 37 -
Hand Eczema 
 
Fig 13 Hand of a patient with mycosis fungoides 
 
 
Hand of a patient with mycosis fungoides imitating chronic hyperkeratotic hand eczema. Oval patches 
of cutaneous T-cell lymphoma are seen on the left arm and forearm. 
 
Bazex’s disease, perifollicular atrophoderma, which is most prominent on the backs 
of the hands, and Howell-Evans syndrome are paraneoplastic diseases, which may 
mimic hyperkeratotic hand eczema (Fitzpatrick 2003). 
 
Table 4 Common differential diagnoses of hand eczema 
 
• Psoriasis 
• Scabies 
• Lichen planus 
• Fungal infection 
• Dermatophytosis 
• Pemphigoid  
• Ichthyoses 
• Malignancies (cutaneous T cell lymphoma) 
• Paraneoplastic diseases (Bazex disease, 
Howell-Evans syndrome) 
• Immunological disorders (dermatitis 
herpetiformis, dermatomyositis) 
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3.7 Histology 
 
 
The various forms of eczema are very similar histologically but differ in their 
clinical presentation. The histology of hand eczema reveals a considerably thickened 
horny layer and an increased number of sweat glands (Rook et al. 1998).  
There are four main stages in the development of eczema. In the early acute stages 
vesication occurs. This occurs in the epidermis and is the result of oedema formation 
called spongiosis. In later stages spongiosis and vesication decrease while 
acanthosis, hyperkeratosis and parakeratosis occur.  
This results in thickening of the prickle and horny layer. All these changes are 
accompanied by vasodilatation and migration of inflammatory cells such as 
lymphocytes, monocytes and macrophages (Hunter et al. 2002). 
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Therapy 
 
 
Table 5 Therapy options for hand eczema 
 
 
• Prevention 
• UV radiation 
• Oral immunosuppressants 
(cyclosporine, methotrexate) 
• Radiotherapy 
• Retinoids (topical, oral) 
• Calcineurine inhibitors (tacrolimus, 
pimecrolimus) 
• Emollients  
• Corticosteroids 
• Antimicrobials 
• Barrier creams 
• Oral disodium cromoglycate (DSCG) 
• Oral ranitidine 
• Gamma-linolenic acid 
• Oral tetraethylthiuramdisulphide 
• Oral triethylenetetramine 
• Iontophoresis 
• Intradermal botulinum toxin 
4.1. Prevention 
 
Preventive measures should always be one of the first objectives in the 
treatment of hand eczema. If a contact factor is the sole cause, identifying and 
eliminating the factor could in theory cure hand eczema. 
 In occupations where hand eczema is very common contact allergens and irritants 
should be avoided by adequate protective measures such as health and safety 
education. This not only means to providing protective measures but also to raise 
awareness regarding this issue.  
Itscher et al. (1996) investigated the attitude of apprentices in the metalworking 
industry towards the risk of occupational skin disorders and protection. It was 
assumed that their attitude at the start of their training would determine their future 
risk behaviour. 79 metal worker apprentices were interviewed by using a 
questionnaire. The authors found that the apprentices were very poorly informed 
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about the risk of developing skin pathology. They stated that they were not well 
informed about the subject and that most of them were not concerned about 
developing occupational skin problems. 
Milkovic-Kraus et al. (1996) propose to use patch testing to risk stratify workers 
before they start their employment. 175 subjects were patch tested before 
employment in the pharmaceutical industry. None of the subjects had contact 
dermatitis prior to testing. There was no positive history of hand eczema. Patch 
testing was positive in 7% or 12 subjects. 7 showed a positive reaction to 1 contact 
allergen, whereas 5 reacted to several contact allergens.  
Kalimo et al. (1999) used an eczema school to improve compliance in an 
occupational dermatology clinic and have reported that worker education could 
improve prognosis. 
It is important to note that this does not only relate to patients with exogenous 
eczema. It has been described earlier that also endogenous hand eczema can also 
be exacerbated by external causes. In particular, Meding (1996) points out that the 
group of atopic subjects carries an increased risk of developing hand eczema and 
suggests that these subjects should particularly be targeted in preventive measures.  
Flyvholm et al. (2005) investigated prevention of work related skin problems among 
gut cleaners in swine slaughterhouses using a randomized controlled intervention 
study. Educational activities were implemented and evidence based 
recommendations given. 495 participants were evaluated by telephone interviews. 
The frequency of eczema on hands or forearms was reduced significantly from 
56.2% to 41%. 
Weisshaar et al. (2007) report about experiences with secondary individual 
prevention of occupational skin diseases among health care workers, cleaners and 
kitchen employees. 791 participants took part in skin protection courses. 82.5% of 
health care workers and 86.3% of cleaners and kitchen employees suffered from 
hand eczema of the atopic, irritant or allergic type. Irritant contact dermatitis as a 
single diagnosis was the most frequent one in both groups.  The participants rated 
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the prevention course as good to excellent. Nearly 80% of the participants attending 
the course had skin lesions. 
4.2 UV Radiation 
 
UVB radiation was administered to 26 patients 4-5 times weekly over 10 
weeks at home and in the clinic. None of the patients cleared during the study. 
However, 17 patients considered themselves as >80% improved (Sjovall and 
Christensen, 1994). 
 
Bayerl et al. (1999) investigated treatment with UVB light versus no phototherapy in 
48 patients with occupational hand dermatitis. In a non-blinded, randomized parallel 
study UVB treatment was administered for 8 weeks to one group. Both groups 
received non-specific emollients. Both groups showed improvement in clinical 
parameters. A significantly better result was seen in terms of lichenification, 
vesiculation and excoriation in the UVB group. 
UVB hand therapy versus whole body UVB versus placebo phototherapy were 
administered to patients. Sjovall et al. (1987) divided 18 patients into three groups. 
One group received UVB radiation to the hands 4 times per week for 8 weeks, while 
the placebo group only received filtered light. In the third group the patients 
underwent hand UVB and whole body UVB+UVA. Of participants receiving hand 
UVB, two cleared, and one cleared in the placebo group. In the whole body 
UVB+UVA group, all hands cleared. 
 
Rosen et al. (1987) looked for differences between oral PUVA therapy versus no 
phototherapy versus UVB therapy in a randomized parallel group study. The authors 
used a left versus right comparison within each treatment group. The 35 patients 
were not blinded.  
In one group, oral PUVA was compared with no phototherapy on the contralateral 
hand for 12 weeks. All the 14 patients used emollients. PUVA treated hands all 
cleared, whereas just one of the untreated hands cleared.  
The second group received UVB on one hand and no phototherapy on the 
contralateral hand. No hand was cleared in any of the 17 patients. The UVB treated 
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hands showed a significant improvement in severity score with a 51% reduction 
compared to 37% in the untreated group. 
The PUVA treated hands of the first group were then compared with the UVB treated 
hands in the second group. All hands treated with PUVA showed clearance. The 
hands, which received UVB treatment, did not clear. However, the number of patients 
with side effects was significantly greater in the PUVA treated group.  
 
The efficacy of superficial radiotherapy and topical psoralen photochemotherapy 
(topical PUVA) was assessed over a 6-week period in a double-blind trial involving 
21 patients. The patients were diagnosed with chronic bilateral constitutional hand 
eczema. One hand was treated with superficial radiotherapy while the other 
underwent treatment with topical 8-methoxy-psoralen and long-wave ultraviolet light 
(topical PUVA). Sheehan-Dare et al. (1989) report significant clinical improvement 
with superficial radiotherapy after 6 weeks, while no difference was seen after 9 or 18 
weeks. No significant difference in symptom severity was reported after 6 weeks with 
a significant improvement in symptomatic control at 9 and 18 weeks in hands treated 
with superficial radiotherapy. 
  
In a double-blind within patient (right-left) randomized study, 15 patients were 
enrolled and the differences between topical PUVA versus UVA were investigated. 
Methoxypsoralen was applied to one hand and inactive liquid to the other. Both 
hands were irradiated with UVA. This was done 3 times per week for 8 weeks. The 
differences between the PUVA and the UVA treated hands were not statistically 
significant, although the means of improvement scores in both groups were 
statistically dfferent (Grattan et al. 1991). 
 
Stege et al. (1997) assessed the effectiveness of cream-PUVA photochemotherapy 
in the treatment of ten patients with chronic recalcitrant palmoplantar eczema. Seven 
patients showed complete remission, and in two patients partial remission was 
reported.  
 
Schempp et al. (1998) investigated the effectiveness of local bath-PUVA therapy in 
28 patients with chronic palmar or plantar eczema or both. The patients did not 
respond to conventional topical treatment. They report excellent or good effects in 
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93% of the patients with dyshidrotic and in 86% of the patients with hyperkeratotic 
eczema.  
 
In another trial the efficacy of PUVA-cream therapy versus PUVA-bath therapy was 
investigated in 12 patients with recalcitrant dermatoses of the palms and soles. A left 
versus right trial design was used. All participants responded well to both treatment 
modalities (Grundmann-Kollmann et al. 1999).  
 
Polderman et al. (2003) investigated 28 patients comparing UVA-1 versus placebo 
therapy. The study was a randomized and double-blind study with a parallel group 
design. UVA-1 irradiation was applied to the hands in one group 5 times per week for 
3 weeks. The placebo group received simulated blue light. The severity score 
decreased significantly in the UVA-1 group.  
 
The effects of localized high-dose UVA-1 irradiation versus topical cream PUVA for 
treatment of chronic vesicular dyshidrotic eczema was evaluated in a study on 27 
patients. Twenty-four of the patients showed a good response to both treatments. 
Dyshidrotic Area and Severity Index scores significantly decreased, and no 
statistically significant difference between the modalities was found (Petering et al. 
2004). 
  
 A study by van Coevorden et al. (2004) compared the efficacy of oral PUVA versus 
topical bath PUVA. In a randomized parallel group study (non-blinded), 158 patients 
were enrolled and were either subjected to oral PUVA (methoxypsoralen) 
phototherapy at home 3 times per week for 10 weeks or topical bath PUVA 
(trioxsalene) in the clinic for 10 weeks. There was a significant improvement in the 
mean of eczema scores in both groups, while no statistically significant difference 
between the groups was seen. A high drop-out rate of 33 patients during treatment 
has been noted. 
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4.3 Oral immunosuppressants 
 
4.3.1 Oral Cyclosporine 
 
The efficacy of cyclosporine A was investigated in seven patients with hand 
eczema. Doses between 1.25 mg/kg and 5 mg/kg/day were used for 2-16 weeks. In 
six of the seven patients, the eczema responded to CyA treatment within a few 
weeks (Reitamo et al. 1994).  
 
Granlund et al. (1996) investigated the effect of oral cyclosporine on disease activity. 
41 patients were enrolled to take part in this randomized parallel group design study 
with partial crossover in the 2nd phase. 17 patients received oral cyclosporine (3 
mg/kg/day) and placebo cream for 6 weeks. The other group underwent topical 
treatment with betamethasone dipropionate 0.05% and placebo capsules. After 6 
weeks there was a crossover of those patients who did not respond to treatment in 
the first 6 weeks. The 3rd phase consisted of the follow-up period of 24 weeks without 
intervention.  
There was improvement in both of the groups, but no statistically significant 
difference between the groups in terms of participant and doctor rated good/excellent 
control and severity scoring.  
 
Another paper by the same group (Granlund et al. 1997) dealt with a different aspect 
of the same trial. The effect of the therapies on the quality of life was compared. 
Quality of life was assessed using the eczema disability index (EDI) at baseline and 
at the end of the treatment. The score was significantly reduced after the treatment 
period in both groups, but no significant difference was reported between the groups. 
 
In a long-term follow up Granlund et al. (1998) then evaluated the efficacy of 
cyclosporine. Seventy-five patients were enrolled. Six were suffering from actinic 
dermatitis, 42 from atopic dermatitis and 27 from chronic hand eczema. These 
patients had been treated with cyclosporine in previous studies and were 
investigated 4 years, 2 years and 1 year, respectively, after the initial treatment.  
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After 4 years, 3 out of the 6 patients with actinic dermatitis showed long-term 
efficacy. Two years after initial treatment of the 37 evaluable patients in the atopic 
dermatitis group 35 were still in remission. 21 of the 27 patients in the chronic hand 
eczema group were still in remission after 1 year. No control groups were used in this 
study. 
 
4.3.2 Oral Methotrexate 
 
Egan et al. (1999) reported use of low-dose oral methotrexate in 5 patients 
with recalcitrant palmoplantar pompholyx. The patients did not respond to 
conventional therapy and showed significant improvement or clearing after addition 
of methotrexate to their treatment.  
 
4.4 Radiotherapy 
 
Four double-blind, placebo-controlled studies investigated the effect of 
irradiation with X-rays.  
King et al. (1984) enrolled 20 patients and used superficial ionising radiation 
fractionated 100 Rad at 45kV once weekly for 3 weeks on one hand and placebo 
irradiation on the contralateral hand. The majority of hands treated with ionising 
radiation achieved clearance or partial clearance after 3-6 months. No improvement 
was seen in the placebo group. The results were not statistically significant. 
 
In a similar study 24 patients were randomized to receive superficial X-ray therapy 
with ionising radiation (100 Rad at 50 kV three times with 31 intervals) on one hand 
and placebo on the other hand. Patients continued treatment with tar paste or steroid 
ointments on both hands. The severity score and the mean grade of eczema were 
significantly lower in the treatment group (Fairris et al. 1984).  
 
Fairris et al. (1985) looked for a significant difference between X-rays and Grenz-
rays. One hand received one Gy of superficial X-ray 50kV, the other 3 Gy of Grenz-
ray 10kV. This occurred three times within a 21-day interval. The severity score was 
significantly lower in the X-ray group compared to the Grenz-ray arm of the study. 
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Superficial X-ray therapy was administered at 0.9 Gy and 50kV on three occasions at 
21-day intervals and was compared to topical PUVA therapy in 25 patients. Topical 
PUVA was applied three times per week for 6 weeks. For both treatments a 
significant improvement compared to pre-treatment scores was seen at 6, 9 and 18 
weeks. Concerning the reduction in severity score (participant-rated scoring), the 
score for superficial radiotherapy was significantly better than topical PUVA therapy 
at 9 and 18 weeks with a p-value of 0.046 and 0.013 respectively. Doctor-rated 
scoring showed that superficial radiotherapy was significantly better after just 6 
weeks.  
 
The effect of Grenz-ray therapy was shown to be statistically significant in terms of 
severity scoring as compared to placebo therapy in 24 patients by Lindelof et al. 
(1987). The patients underwent ionising radiation with Grenz-rays (300 Rad) once 
weekly for 6 weeks and placebo radiation was given on the contralateral hand.  
 
Cartwright et al. (1987) used a similar approach and studied 30 patients. One hand 
was irradiated with X-rays 300 Rad 10 kV three times at 21-day intervals. The 
contralateral hand received placebo radiation. This study did not show any significant 
difference between the treatment and placebo group. The patients in this study were 
suffering from bilateral, symmetric, constitutional hand eczema, which had been 
resistant to previous treatment.  
4.5 Retinoids 
 
4.5.1 Topical retinoids 
 
Hanifin et al. (2004) looked at the effect of topical retinoids. In a randomized, 
parallel group study, 55 patients either applied bexarotene 1% gel (stepwise from 
once every other day to 3 times daily for 22 weeks) or bexarotene 1% gel stepwise 
plus mometasone furoate 0.1% ointment twice daily. The third group used a 
combination of bexarotene gel stepwise plus hydrocortisone 1% ointment. All groups 
also used daily emollients. 
Treatment success was defined as clearance of more than 90%. This was achieved 
in 39% of the bexarotene group, 46% of bexarotene-mometasone group and 21% of 
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the bexarotene-hydrocortisone group. The differences between the groups were not 
statistically significant.  
 
4.5.2 Oral retinoids 
 
Bollag and Ott (1999) evaluated oral 9-cis-retinoic acid for treatment of chronic 
hand eczema. They treated 38 patients in an open-label study. The subjects received 
a once-daily dose of 20-40 mg for a mean duration of treatment of 2.3 months. 55% 
showed a very good response, 34% a good response, and 5.5% a moderate 
response, and 2 patients showed no response. The response was recorded using a 
total lesion/symptoms score.  
 
Oral acitretin was compared to placebo capsules. Thestrup-Pedersen et al. (2001) 
randomized 29 patients to receive either 30 mg of acitretin daily for 8 weeks or 
placebo capsules for the same amount of time. The observers were blinded in this 
study. According to the authors there was no blinding of the patients due to the side 
effects (dry lips) of acitretin treatment. There were significant reductions in scores for 
hyperkeratosis (50%), fissures (67%) and scaling in the acitretin group. A significant 
difference to the placebo group has not been noticed.  
Capella et al. (2004) investigated the use of acitretin 25-50 mg/day for 1 month, 
versus a conventional topical treatment (betamethasone and salicylic acid ointment). 
42 patients with chronic hyperkeratotic palmoplantar eczema were enrolled in this 
single-blind and matched-sample design trial. The oral retinoid was significantly 
better than the topical treatment after 30 days with significant persistence 5 months 
after suspension of acitretin.  
Recently, Ruzicka et al. (2004) used three different doses of 9-cis-retinoic acid, 
another retinoid (alitretinoin) in comparison with placebo capsules. This trial was a 
randomized double-blind multicentre study with 319 participants. The patients were 
allowed to use standard emollients. In addition, they underwent treatment with 10 
mg, 20 mg, 40 mg or placebo capsules daily for 12 weeks. 
Significant differences were found in terms of clearance or almost clearance in all 
alitretinoin groups compared to the placebo group. Statistically significant differences 
were also reported for reduction in severity (improvement in dermatological life 
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quality index) in all intervention groups. This was true for participant and investigator 
scoring. 
  
In a phase 3 trial, Ruzicka et al. (2007) assessed the efficacy and safety of 
alitretinoin in the treatment of severe chronic hand eczema refractory to topical 
corticosteroids. 1032 patients from a total of 111 outpatient clinics in Europe and 
Canada were enrolled between 2004 and 2006 and were randomized in this double-
blind, placebo-controlled prospective multicentre trial. The patients were aged 18 to 
75 and were eligible if diagnosed with severe hand eczema of more than a 6-month 
duration, which was refractory to standard therapy. 
The patients received placebo, 10 mg or 30 mg of oral alitretinoin once daily for up to 
24 weeks. All patients applied emollient cream frequently. 
Patients who cleared or almost cleared after 12 weeks stopped treatment at that 
point. The others continued for up to 24 weeks. Further monitoring of responders for 
24 weeks assessed relapse. 
The Physician’s Global Assessment was used to determine overall chronic hand 
eczema severity, with a response defined as clear or almost clear hands. Patients in 
the 30 mg group responded better than in the 10 mg group. 48% of patients treated 
with 30 mg of alitretinoin showed a response. A 75% mean reduction in disease 
signs and symptoms was reported.  
The treatment was overall well-tolerated. Headaches and mucocutaneous events 
(dry skin, dry lips, and cheilitis) were the most commonly described side effects in a 
dose-dependent manner. Increased serum cholesterol and triglyceride levels and 
reduced thyroxin and TSH levels were the most commonly reported abnormalities in 
laboratory parameters. 32% of patients relapsed during the 24-week follow-up period. 
Efficacy was observed in all types of hand eczema with the highest response rates in 
the hyperkeratotic group (85%). 
This trial is consistent with previous trials investigating the efficacy of retinoids in the 
treatment of chronic hand eczema.  The trial is large with 1032 patients from a total 
of 111 outpatient clinics in 11 countries. Another feature that makes this study special 
is the fact that it is one of a few randomized and double-blind, placebo-controlled 
studies investigating this therapy. 
The study underscores the fact that alitretinoin is not just a safe and powerful therapy 
option but also a long-lasting one. 68% of patients did not show relapse during the 24 
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week follow up period. Especially important is the low side effect profile. Other 
treatment options in addition to topical corticosteroids such as methotrexate, 
cyclosporine or mycophenolate mofetil are associated with a multitude of side effects.  
It will also be important to investigate the effect of concomitant use of other therapies 
such as corticosteroids on response and relapse rates. 
 
4.6 Calcineurine inhibitors 
 
Schnopp et al. (2002) compared topical tacrolimus with a topical corticosteroid 
(mometasone furoate). A randomized, observer-blinded, within-patient left-right 
design was used, and 25 patients enrolled in this study. Tacrolimus 0.1% ointment 
was applied twice daily for 1 month, and mometasone furoate 0.1% ointment was 
applied to the contralateral hand. Improvement was shown in both groups with a 
reduction of more than 50% of the dyshidrotic area and severity index. No significant 
difference could be shown between the groups. The p-value for the tacrolimus group 
was 0.559. 
 
Thelmo et al. (2003) investigated efficacy of topical tacrolimus 0.1% in hand and/or 
foot eczema. In this open-label pilot study, 25 adults applied the ointment three times 
daily for 8 weeks. The authors report significant improvement in erythema, scaling, 
indurations, fissuring, composite severity and pruritus. Significant improvement 
persisted after two weeks in scaling and composite severity. 
 
Pimecrolimus 1% cream was applied twice daily in a trial involving 12 patients. 
Evening application was followed by overnight occlusion. Disease state at day 22 
improved in 11 of the patients. 73.6% of the pimecrolimus blood concentrations 
remained below the limit of quantitation (Thaci et al. 2003).  
 
A large multicentre trial looked at the effect of topical pimecrolimus cream versus the 
vehicle. The study was randomized and double-blinded. 294 patients were divided 
into two groups and either applied pimecrolimus 1% cream or vehicle twice daily for 3 
weeks. In both groups the evening application was followed by 6 hours of occlusion. 
All the hands in the pimecrolimus group and 17% in the control group cleared or 
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almost cleared. The difference did not reach statistically significant levels (Belsito et 
al. 2004). 
 
A similar trial compared pimecrolimus with vehicle treatment. 48 patients were 
randomized into 4 groups. The trial was double-blind. The first group applied 
pimecrolimus 1% cream twice daily for 6 weeks. The second group applied 
pimecrolimus 1% cream under occlusion for the same time period. The two control 
groups applied vehicle under the same circumstances. Cherill et al. (2002) report that 
at the end of the treatment, the results of the occluded pimecrolimus groups seemed 
to be superior. However, only at day 29 was there a statistically significant difference. 
 
4.7 Emollients 
4.7.1 Bland emollients 
 
Bielfeldt et al. (1998) tested the efficacy of a new hand care system consisting 
of cleansing oil and a care cream in 37 patients with irritant hand eczema. In 24 
patients the use of the hand care system for three weeks resulted in improvement. A 
significant and lasting increase in skin moisture was noted. The hand care system 
consisted of cleansing oil containing mostly natural lipids and a care cream 
containing dexpanthenol and vitamin E. 
 
In another study Berndt et al. (2000) studied a barrier cream and its moisturizing 
vehicle in a randomized, double-blinded study. Two groups consisting of 25 hospital 
nurses were asked to use either the verum or vehicle for 4 weeks. The authors 
reported no significant differences between barrier cream and vehicle in terms of 
clinical skin status and improvement in hydration of the stratum corneum.  
 
Two skin protective creams were evaluated for the treatment of irritant dermatitis in 
hairdresser apprentices. A clinically significant improvement was seen in skin 
dryness, redness and scaling after 2 and 4 weeks of treatment in most subjects. In 
addition, transepidermal water loss and skin colour were significantly decreased, and 
horny layer skin hydration increased (Bock et al.  2001).  
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In a randomized parallel group study Kucharekova et al. (2003) compared regular 
petrolatum-based emollients with emollients containing ceramides. They investigated 
32 patients with bilateral chronic hand dermatitis and found no statistically significant 
difference between the groups. Observers were blinded in this study. 
 
Mygind et al. (2006) studied a high-fat petrolatum-based moisturizer in wet-work 
occupations in a randomized and controlled intervention study. The patients were gut 
cleaners in Danish swine slaughterhouses. Telephone interviews and questionnaires 
were used, and 644 participants were included. In the intervention group the 
frequency of eczema was reduced significantly.  
 
4.7.2 Corticosteroid preparations 
 
Moller et al. (1983) studied 55 patients with chronic symmetrical hand eczema 
who had been brought into remission in a self-controlled, left-right randomized study. 
Fluprednidene acetate was compared with clobetasol propionate. No relapses were 
observed in 70% of hands treated with clobetasol and in 30% of hands treated with 
fluprediden. 
 
Two strengths of desonide cream 0.1% and 0.05% were investigated in a within-
patient left-right study. In 46 patients there was no significant difference observed 
(Uggeldahl et al. 1986). 
 
Bleeker et al. (1989) reported no significant difference in a double-blind randomized 
parallel group study comparing fluprednidene cream versus betamethasone valerate 
cream. The outcomes under investigation were investigator rated control, reduction in 
severity and side effects. In both treatment groups the majority of patients showed a 
reduction in severity of over 50%.  76 patients with different subtypes of hand 
eczema were investigated for 3 weeks.  
 
Betamethasone dipropionate film-forming lotion was compared to a thickened 
solution containing the same corticosteroid.  In this double-blind randomized parallel 
group study, 58 patients were involved. There was an 82% reduction in severity in 
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the polyacrylic film-forming lotion as compared to 38% in the thickened solution 
(Gupta et al. 1993). 
 
In a 30-week prospective, open, randomized trial Veien et al. (1999) investigated 106 
patients who were treated for 9 weeks with mometasone furoate until clearance of 
symptoms. The patients who cleared were then enrolled in a parallel group design 
(non-blinded) trial. They underwent treatment with mometasone furoate 3 times per 
week, twice per week or with emollients only for up to 36 weeks. Daily treatment for 3 
weeks controlled the symptoms of 50 of the 106 patients. 29 patients needed 6 
weeks of treatment for clearance and 27 needed 9 weeks.  
During the maintenance phase, patients with more intensive treatment showed less 
recurrence. 83% of the patients who were treated three times per week, 68% of 
patients who were treated twice weekly and  26% of patients who were treated with 
emollients only had no recurrences (p = 0.001). 
 
4.8 Antimicrobials 
 
Hill et al. (1998) investigated topical antibacterial agents in combination with 
topical steroids in a randomized, parallel-group design and non-blinded study. 57 
patients with a diagnosis of hand eczema and suspected or confirmed infection 
applied betamethasone valerate 0.1% and clioquinol 3% cream twice daily for 4 
weeks. 53 patients used betamethasone valerate 0.1% and fusidic acid 2%. Both 
groups showed a significant reduction in severity scores, but no significant difference 
between the groups was observed. 
 
4.9 Barrier Creams 
4.9.1 Topical Quaternium-18-Bentonite 
 
Fowler (2001) investigated a skin moisturizing cream containing quaternium-
18-bentonite.  37 patients were enrolled into this study and were given study cream 
for routine application. After 2, 4 and 8 weeks patients and observers evaluated skin 
parameters, and steroid cream use was recorded. A statistically significant 
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improvement of 50% (p-value<0.001) was noted in redness, scaling, fissuring, 
blistering and pruritus. Topical corticosteroid use was reduced in 29 of 33 patients 
who completed the study. 
 
4.9.2 Protective foam containing dimethicone and glycerine 
 
Fowler (2000) studied 31 subjects using protective foam containing 
dimethicone and glycerine. The subjects with allergic, irritant or combined hand 
eczema applied the foam routinely. At weeks 2 and 6, skin was evaluated using 
parameters including redness, scaling, fissuring, blistering and pruritus.  
28 patients completed the study. The author reports a significant decrease in the skin 
parameter score (p-value<0.001). Topical steroid use decreased in 53.6% of the 
subjects. 
 
4.10 Others 
4.10.1 Oral Disodium cromoglycate (DSCG) 
 
Twenty-four patients with pompholyx and a positive patch test to nickel, 
confirmed by reaction to oral nickel challenge, were randomized into three groups. 
The investigators were blinded. A low nickel diet was used for 3 months in 8 patients, 
and oral disodiumcromoglycate was given 1500-2000 mg three times daily for 3 
months in 9 patients and 7 patients were not treated. 
Improvement in itching was reported in 5 out of 8 in the disodiumcromoglycate group, 
1 out 8 in the nickel diet group and none out of the control group. The difference 
between the disodiumcromoglycate group and the control group was statistically 
significant. The reduction in the number of vesicles at 12 weeks was also statistically 
significant between the DSCG and the nickel diet group and the DSCG and control 
group (Pigatto et al. 1990). 
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4.10.2 Oral Ranitidine 
 
Veien et al. (1995) studied 47 patients in this double-blind trial testing the 
effect of oral ranitidine (300 mg) twice daily for 16 weeks compared to placebo 
treatment. Both groups received emollient and topical steroid treatment. 17 out of the 
23 patients in the treatment group cleared or almost cleared. The same was true for 
just 8 of the 24 placebo patients. This was a statistically significant result with a p-
value of 0.02. The reduction in terms of severity scoring was not significant between 
the groups. 
 
4.10.3 Gamma-linolenic acid (GLA, evening primrose oil) 
 
Thirty-nine blinded patients received either 50 mg of GLA daily for 16 weeks or 
placebo capsules. Whitaker et al. (1996) allowed both groups to use topical steroids 
and emollients. There was no statistical difference in reduction of severity scores 
between the two groups. The GLA-group showed significant improvement for all 
components of the severity score used in this study. 
 
4.10.4 Oral Tetraethylthiuramdisulphide (TETDS) 
 
Thirty nickel-sensitive women with pompholyx-type hand eczema received 
either 50 mg of TETDS daily for the first week, which increased to 200 mg/day for at 
least 6 weeks, or placebo tablets. Both groups used topical corticosteroids and 
emollients. 5 out of 11 in the treatment group “healed” as compared to 2 out of 13 in 
the placebo group. There was a significant improvement in scaling and frequency of 
flares and in the sum of the parameters in the TETDS group (Kaaber et al., 1983).  
4.10.5 Oral Triethylenetetramine 
 
Burrows et al. (1986) investigated oral triethylenetetramine versus placebo in 
23 patients. A randomized parallel group, double-blinded study with cross-over was 
used. The trial was terminated before the cross-over phase due to reports of 
teratogenicity of oral triethylenetetramine in rats. One treatment arm received 300mg 
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of oral triethylenetetramine daily for 6 weeks, while a placebo was used in the other 
group. No significant improvement was found. 
 
4.10.6 Iontophoresis 
 
Twenty patients were enrolled in a randomized, self-controlled study 
investigating iontophoresis. One hand received pulsed direct current iontophoresis 20 
times during 3 weeks. The contralateral hand was not treated. Both hands received 
steroid-free tar solution and zinc paste. The observers were blinded. There was a 
statistically significant difference in the median pruritus score, median total score and 
median vesicle formation in the iontophoresis treated hands as compared to the non 
treated hands (Odia et al. 1996). 
 
4.10.7 Intradermal botulinum toxin 
 
Swartling et al. (2002) investigated the effect of intradermal injections of 
intradermal botulinum toxin A in ten patients with vesicular hand dermatitis. The 
patients were treated on one hand with intradermal botulinum toxin with the untreated 
side as a control. The patient had to self-assess at follow-up at weeks 5 to 6. Seven 
out of ten patients experienced a good or very good effect. A decrease in itching was 
reported with mean of 39% on the treated side compared with an increase of 52% on 
the untreated side.  
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Results of Cream-PUVA photochemotherapy study 
 
For the purpose of this dissertation, data regarding 107 patients suffering from 
refractory hand eczema, who were treated with cream-PUVA photochemotherapy at 
the Phototherapy Unit at the Department of Dermatology, Faculty of Medicine of 
Heinrich Heine University, Düsseldorf, was collected and analysed (Stege et al. 
2007). 
 
Assessment before therapy 
In all patients the diagnosis of hand eczema was clinically and histologically proven. 
The patients were classified to one of the following subgroups: hyperkeratotic 
rhagadiform hand eczema, dyshidrotic hand eczema, atopic hand eczema and 
contact hand eczema. 
 
Phototherapy 
All patients received cream-PUVA photochemotherapy four times a week (Monday, 
Tuesday, Thursday, Friday). The 8 L-MOP containing cream consists of 0.0012% 8-
MOP in about 67% Unguentum Cordes (Ichthyol-Gesellschaft Cordes, Hermanni & 
Co (GmbH & Co) KG, Hamburg, Germany) and 33% purified water. After 1 hour of 
incubation time, UVA irradiation was given by a PUVA 180 and PUVA 200 irradiation 
unit (Waldmann Lichttechnik, Villingen-Schwenningen, Germany) equipped with 
Waldmann F15W/T8 PUVA bulbs, F8W/T5 respectively, emitting a mean radiation 
intensity of 12.5 mW/cm2. The initial UVA doses ranged between 1-2 J/cm2 
depending on the skin phototype. The UVA dose was increased after every treatment 
unless side effects such as erythema occurred. Increments were done following a 
fixed protocol, which allowed increments of 0.5 J/cm2 UVAR up to a dose of 4 J/cm2.  
Above this threshold the UVA dose was increased by 1 J/cm2 UVAR.   
 
Therapy was continued until symptoms had cleared or no further improvement could 
be determined. The patients were assessed on a weekly basis to determine 
improvement and symptomatic control. 
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Determination of clinical response 
Clinical response was determined by 3 outcomes: complete remission, partial 
remission or no response. 
 
Results 
107 (53 female; 54 male) patients were routinely treated for hand eczema and 
underwent cream-PUVA photochemotherapy. 54 male patients and 53 female 
patients were treated. The average patient age was 45.8 years. The patients 
underwent an average of 28.6 treatments. 
The patients were diagnosed clinically and histologically and were classified in one of 
the following subgroups: 47 patients with hyperkeratotic rhagadiform hand eczema, 
43 patients with dyshidrotic hand eczema, 12 patients with atopic hand eczema and 
5 patients with contact hand eczema (Table 6). 
 
Table 6 Characterisation of patients with refractory hand eczema treated with cream-   PUVA 
photochemotherapy 
Diagnosis (hand eczema) Patient Number Male Female
Cumulative Dose 
(J/cm2) Treatments 
All patients 107 54 53 125.24 28.6 
Hyperkeratotic 
rhagadiform 47 29 18 155.24 30.12 
Dyshidrotic 43 20 23 130.67 28.49 
Atopic  12 3 9 171.52 37.67 
Contact  5 2 3 43.52 18.2 
 
 
Among the 107 patients, complete remission was found in 35 patients (32.7%). 36 
patients showed a partial response (33.6%). 20 patients showed no response to 
treatment (18.7%) and 16 patients withdrew from treatment for personal reasons 
(Figure 14). 
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Fig 14 Overall outcome of therapy subdivided into complete remission, partial remission, no response 
and withdrawal from treatment 
35
36
20
16
0
5
10
15
20
25
30
35
40
complete remission partial remission no response w ithdraw al from
treatment
Outcome
Pa
tie
nt
 N
um
be
r
 
Fig 15 Outcome of therapy in the hand eczema subgroups into complete remission, partial remission and 
no response to treatment 
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Subgroup analysis (Fig. 15) revealed that patients suffering from hyperkeratotic 
rhagadiform (34 out of 40 patients; 85%) and dyshidrotic hand eczema (30 out of 37 
patients; 81.1%) received a higher benefit compared to patients suffering from atopic 
(6 out of 9 patients) or contact hand eczema (1 out of 5 patients).  
 
In 21 out of 54 (38.9%) male patients, complete remission of symptoms was 
achieved, and in 18 patients (33.3%) partial response was achieved. Eight patients 
did show no response to treatment. Seven male patients withdrew from treatment for 
personal reasons (Fig. 16).  
 
Analysis of the female subgroup (53 patients) reveals complete remission in 14 
patients (26.4%), a partial response in 18 patients (34%) and no response in 12 
patients. Nine patients withdrew from treatment for personal reasons (Fig. 16).  
Therefore, 39 out of 47 (83%) treated male and 32 out of 44 (72.7%) treated female 
patients either showed complete or partial remission.  
 
 
Fig 16 Overall outcome of therapy in male and female patients subdivided into complete remission, 
partial remission, no response and withdrawal from treatment 
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Except for erythema reaction in two patients, which did not cause cessation of the 
treatment, no other side effects occurred. In general, cream-PUVA therapy was well 
tolerated in all treated patients. 
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Fig 17 Hand of a patient with dyshidrotic hand eczema before (left) and after (right) cream-PUVA 
therapy 
 
 
Fig 18 Hand of a patient with hyperkeratotic hand eczema before (left) and after (right) cream-PUVA 
therapy 
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Discussion 
 
6.1 Hand eczema 
 
Hand eczema is a very common and widespread condition, which was 
presumably first described in the 19th century. Due to the high incidence and 
prevalence of the pathology, it has enormous socio-economic consequences. The 
varying degrees of severity also mean that the condition has a massive impact on 
patients’ quality of life. 
There are many reasons why this disease can be a very difficult pathology to treat for 
the medical practitioner and dermatologist.  
Eleven different morphological subtypes of hand eczema have been described in 
preceding chapters according to classifications published in the literature.  
This and the fact that several endogenous and exogenous factors play a role in the 
aetiology underscore the multifactorial nature.  
However, the multifactorial nature also allows therapy to be directed at different sites 
simultaneously.  
Immunological or psychosomatic factors and dyshidrosis are important to target 
when attempting treatment as well as exogenous causes such as contact allergens, 
ingested allergens or infections, which should be avoided. 
 
Genetic factors undoubtedly play an important role, but it is the phenotype of these 
genes that can be modified by effective and supportive treatment. 
A change in the barrier function of the skin seems to increase the irritability of the 
skin. Palmer et al. (2006) have shown that the epidermal barrier protein filaggrin 
seems to play a key role. Combined with an enhanced releasability of cytokines and 
a proposed dysfunction of immune cells such as T-cells and B-cells, this results in 
the eczematous changes in the skin. 
  
Therapy has to target all of the above-mentioned factors, sometimes in combination, 
in order to be effective and long lasting. 
In this thesis 16 different treatment modalities of 53 major trials over the last 40 years 
have been described and discussed.  
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Table 7 Overview of trials according to type of treatment, number of trials and number of patients 
 
Treatment Number of Trials Number of Patients 
UV radiation 12 430 
Oral cyclosporine 4 48 
Oral methotrexate 1 5 
Radiotherapy 5 123 
Topical retinoids 1 55 
Oral retinoids 5 1460 
Calcineurine inhibitors 5 391 
Bland emollients 5 738 
Topical corticosteroids 5 341 
Antimicrobials 1 116 
Barrier creams 2 68 
Oral disodium cromoglycate 1 24 
Oral ranitidine 1 47 
Gamma-linolenic acid 1 39 
Oral tetraethylthiuramdisulphide 1 30 
Oral triethylenetetramine 1 23 
Iontophoresis 1 20 
Intradermal botulinum toxin 1 10 
 
 
These trials cover treatments ranging from bland emollients (5 trials) or barrier 
creams (2 trials), which address the skin barrier dysfunction, to immunosuppression 
or immunomodulation with corticosteroids (5 trials), cyclosporine (4 trials), 
calcineurine inhibitors (5 trials) or retinoids (6 trials) amongst others addressing the 
increased activation of the immune system. Other treatments are UV radiation (12 
trials), radiotherapy (5 trials), antimicrobials (1 trial) and methotrexate (1 trial).  
One trial each covers oral disodium cromoglycate, oral ranitidine, gamma-linolenic 
acid, oral tetraethylthiuramdisulphide, oral triethylenetetramine, iontophoresis and 
intradermal botulinum toxin (Table 7). 
 
Several problems have been noted when looking at those trials in detail. 
 
Including the submitted trial by Ruzicka et al. (2007) with 1032 patients, a total of 
3968 patients were enrolled in the 53 trials. These trials range from interventional 
trials without a control group, blinding or randomization to double-blind, randomized 
and controlled trials. Most studies however lie somewhere in between those 
parameters. 
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Careful analysis shows that out of the 53 trials, just 8 studies fulfil the criteria for a 
double-blind, randomized control trial.  
Five out of these eight trials use a within patient (left hand right hand) control. This 
leaves 3 trials with a clear randomization procedure, double-blinding of patients and 
investigators and separate control groups.  
Many of the other trials claimed to be randomized, but 21 studies did not describe a 
clear randomization procedure with uncertainties in allocation concealment. 
It can be argued that a within patient control can be sufficient, particularly when 
looking at topical treatment for hand eczema in particular. On the other hand it 
cannot be fully excluded that, for example, local radiation or emollient intervention on 
one hand may have systemic effects via immunomodulation or suppression and, 
consequently may bias the result of the intervention on the other hand. 
Crosscontamination between the hands can have the same effect. 
Due to different treatment modalities, investigators have argued that blinding was not 
possible or very difficult practically as patients could perceive specific side effects of 
medication.  This was especially true when topical therapy was compared to oral 
therapy or radiation. This resulted in observation bias in many of the mentioned trials. 
 
This leaves a patient population of 1520 patients in 8 trials to give evidence for 
treatment of hand eczema. Using even stricter criteria leaves 1392 patients in three 
purely randomized controlled, double-blind trials. 
This number includes the submitted trial by Ruzicka et al. (2007) investigating oral 
alitretinoin in a patient population of 1032 in a multicentre trial. The second study also 
investigated alitretinoin (Ruzicka et al. 2004). The third trial investigated the effect of 
oral cyclosporine on hand eczema in 41 patients (Granlund et al. 1996).  
The remaining five trials with left versus right within-patient control investigated 
PUVA therapy and radiotherapy.  
One trial looked at superficial radiotherapy versus treatment with topical 8-
methoxypsoralen and long-wave ultraviolet irradiation (topical PUVA) in 25 patients 
(Sheehan-Dare et al. 1989). The other four investigated use of radiotherapy in 103 
patients (Fairris et al. 1984; Fairris et al. 1985; Lindelof et al. 1987; Cartwright et al. 
1987).  
 - 64 -
Hand Eczema 
 
Considering the prevalence of hand eczema and its socio-economic implications, it is 
surprising that most data on treatment of this disease stems from a patient population 
of about 1500 patients. 
Another important point is that very few trials used a standard therapy as a 
comparator. When looking at the trials a placebo or a vehicle is most commonly used 
as comparator.  
Most specialists would agree that topical steroids or UV light therapy is used as first 
line treatment of hand eczema. This point is also reflected and underscored by the 
fact that 22 of the studies investigated UV radiation, bland emollients or 
corticosteroids. 
Using these two therapies as comparators would enable readers to draw conclusions 
about the efficacy of the new intervention as compared to “standard therapies”.  
One of the exceptions is Granlund et al. (1996) who investigated the effect of oral 
cyclosporine on disease activity on 41 patients. Seventeen patients received oral 
cyclosporine (3 mg/kg/day) and placebo cream for 6 weeks. The other group 
underwent topical treatment with betamethasone dipropionate 0.05% and placebo 
capsules. The follow-up period was 24 weeks.  
 
Duration is another important issue when looking at the trials. Most studies do not 
treat or follow patients up for a time period longer than three to four months. As hand 
eczema is a chronic disease with frequent relapses, a longer study period or follow 
up data regarding long term efficacy and relapses would be desirable. 
The certainty of diagnosis of hand eczema was not discussed by the studies 
sufficiently. No study stated a specific procedure other than diagnosis by a specialist.  
Most studies also enrolled patients with subcategories of hand eczema. This fact can 
prove as problematic as well. Different subcategories of hand eczema might be more 
or less susceptible and amenable to treatment modalities than others. Separate 
analyses of subcategories of hand eczema would therefore be desirable but were 
undertaken in just a few of the studies.  
Some of the trials also included other pathologies than hand eczema. Capella et al. 
(2004) reports at least 8 patients with psoriasis. Grundmann-Kollmann et al. (1999) 
also describe treatment of severe recalcitrant dermatoses of the palms and soles 
with PUVA-bath versus PUVA-cream therapy. This makes careful analyses and 
conclusions about the efficacy of treatment more difficult. 
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Just eight of the studies used intention-to-treat analysis when analysing the data 
regarding patients that dropped out of the studies or were lost to follow up. 
Various scoring methods have been used and described in the studies.  
No scoring methods have been validated so far. This is one of the biggest 
shortcomings of the data as outcome is very difficult to interpret. Primary and 
secondary outcomes have been defined in only 11 trials. However, even if they were 
defined, the data cannot be compared due to the different scoring methods. 
  
Van Coevorden et al. (2006) used data from an open-label randomized controlled 
trial on 158 patients with severe chronic hand eczema to investigate scoring methods 
for severity of hand eczema. The authors investigated correlations between different 
severity scoring methods including physician-rated severity scores, patient-rated 
severity scores, a burden of disease questionnaire (DLQ1, the Dermatology Life 
Quality Index). They report that only desquamation and infiltration of the physician-
rated severity score were significantly correlated with patient-rated severity scores. 
Therefore, they concluded that patient satisfaction is not guaranteed when 
improvement in the visible aspects of hand eczema is achieved by treatment. This 
study underscores the variable nature of severity scores used in different studies. 
  
Hand eczema has major impact on patients’ quality of life. In order to find an effective 
treatment trials have to take the quality of life score into consideration. One study 
looked at this issue. Granlund et al. 1997 investigated the effect of oral cyclosporine 
on quality of life. Quality of life was assessed using the eczema disability index (EDI) 
at baseline and at the end of the treatment. 
 
Comparable findings and deficiencies of hand eczema trials have also been 
described by van Coevorden et al. (2004) who analysed 90 studies and by Diepgen 
et al. (2005) who looked at 100 studies. The latter identified 31 studies as 
randomized clinical trials dealing with different interventions. In the EDEN hand 
eczema survey the former group reported that out of 90 studies only 31 were 
randomized controlled studies with only 11 reporting adequate eligibility criteria. They 
also found that just 10 studies described the randomization method and 8 studies 
had adequate concealment of allocation with only four reporting an intention-to-treat 
analysis. They concluded that most trials in hand eczema are not randomized 
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controlled and that due to the poor quality most studies are not sufficient to be used 
in clinical practice. 
 
6.2 Cream-PUVA photochemotherapy in the treatment of patients 
with treatment refractory hand eczema 
 
Cream-PUVA photochemotherapy was established by our group around 10 
years ago with the objective of optimising and simplifying topical modalities of 
photochemotherapy such as bath-PUVA photochemotherapy (Stege et al. 1997). In 
previous years, cream-PUVA photochemotherapy became an alternative to bath-
PUVA photochemotherapy especially for localised, regionally restricted skin diseases 
or lesions.  
Bath-PUVA photochemotherapy is the treatment of choice for topical therapy of large 
areas, while limiting systemic photosensitisation or side effects. Cream-PUVA 
photochemotherapy includes these advantages of bath-PUVA photochemotherapy, 
but also offers the possibility of targeting regionally restricted skin lesions. Due to the 
localised photosensitisation interference of the treatment with the patients’ quality of 
life is limited. Patients do not have to wear UVA-absorbing sunglasses and reduction 
of their outdoor activities during treatment period is limited to only a few hours. The 
reduction of their outdoor activities can be avoided by using simple UV-protection 
strategies such as wearing gloves or covering sensitized skin areas.  Compared to 
bath-PUVA photochemotherapy cream-PUVA therapy offers several advantages. 
The risk of developing erythema is low and handling of the treatment is easy and 
safe. As compared to bath-PUVA the therapy can be performed with less of an 
investment effort regarding the equipment and training of the staff. 
Application of the cream at home results in a moderate photosensitisation lasting 1-2 
hours. This again improves quality of life and also reduces the logistic effort in 
dermatology practices. In cream-PUVA photochemotherapy the opportunity to 
sensitise each skin area selectively without any difficulties is the most striking and 
charming advantage.  
Recently, several studies have already proven the efficacy of cream-PUVA 
photochemotherapy in the treatment of hand or foot dermatoses (Neumann et al. 
2006 and Petering et al. 2004) or psoriasis (Grundmann-Kollmann et al. 2004). The 
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high significance of cream-PUVA therapy is underscored by its use as a comparative 
established treatment in all those trials.  
The comparison between cream-PUVA photochemotherapy and high-dose UVA-1 
treatment for hand eczema showed an equal response rate in each study arm 
(Petering et al. 2004).  
In both regimes the mode of action is induction of apoptosis in skin-infiltrating T cells 
(Yamauchi et al. 2004). In fact, high-dose UVA-1 treatment did not require 
photosensitization but required high amounts of energy and a huge cumulative UVA 
dosage. From a practical and economic point of view cream-PUVA 
photochemotherapy is also easier and cheaper to perform than a high-dose UVA-1 
therapy. This is because of cheaper devices, shorter irradiation times and lower 
energy consumption. Acute side effects are low in both regimens.  
The photocarcinogenic risk of high-dose UVA-1 has not yet been determined but is 
estimated to be low.  
The photocarcinogenic risk of topical photochemotherapy has been found to be low 
(Hannuksela-Svahn et al. 1999) in comparison with systemic PUVA (Stern et al. 
1997). Therefore, no benefit can be claimed in favour of UVA-1 for the treatment of 
chronic hand eczema. 
Palmoplantar psoriasis is not a type of eczema but has to be taken into consideration 
as a differential diagnosis. Use of monochromatic excimer light was effective for 
palmoplantar psoriasis. Direct comparison of cream-PUVA and monochromatic 
excimer light did not elaborate any statistically significant differences for this 
diagnosis (Neumann et al. 2006). Successful treatment of hand eczema patients 
using excimer light has not yet been reported.  
In a direct comparison of bath-PUVA versus cream-PUVA photochemotherapy for 
the treatment of severe hand and foot dermatoses, both regimens showed equivalent 
efficacy (Grundmann-Kollmann et al. 1999). Moreover, the use of cream-PUVA 
photochemotherapy was able to increase the efficacy of narrowband UVB in the 
treatment of psoriasis (Grundmann-Kollmann et al. 2004). 
 
Here we report our experience with 107 patients routinely treated with cream-PUVA 
photochemotherapy for refractory hand eczema between 1996 and 2004. It is 
important to note that the patients were not recruited for a trial but treated on a 
routine basis.  Known trial-associated benefits which cause an increased healing 
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such as intense care, placebo effects or a protocol-based optimized medical 
treatment can therefore be excluded in our retrospective study.     
 
Cream-PUVA photochemotherapy can be used as an alternative to other treatment 
modalities with similar efficiency such as oral retinoids, topical corticosteroids or 
radiation therapy. Direct comparison of efficacy of cream-PUVA versus alitretinoin 
has not yet been conducted, but in analogy to current practice, in psoriasis cream-
PUVA photochemotherapy in combination with alitretinoin therapy may be an 
interesting approach to investigate in future trials. 
The major disadvantage of topical application of corticosteroids is a sudden rebound 
after cessation of the drug. A maintenance therapy can reduce the risk of a rebound 
but is, of course, associated with side effects associated with long-term topical use, 
especially the induction of atrophy, which decreases the barrier function of the skin.  
A sudden rebound has not been reported or observed following cream-PUVA 
therapy. Recently, the benefit of topical use of calcineurine inhibitors for eczematous 
dermatoses has been controversial because of putative induction of lymphomas 
(Arellano et al. 2007) but the risk if any, appears to be minimal. It has to be 
mentioned that tacrolimus is not licensed specifically for hand eczema. Use could be 
limited due to the lower efficacy on hands as compared to other skin areas.  
 
Our study indicates and underscores the fact that cream-PUVA is an effective and 
useful treatment option for hand eczema not only in a clinical trial but even in an 
everyday setting.  
78% of treated patients either showed complete or partial remission with similar 
efficacy in three of the four different subgroups.  
85% of treated patients with hyperkeratotic rhagadiform hand eczema and 81.1% of 
treated patients with dyshidrotic hand eczema either showed complete or partial 
improvement. Six out of 9 treated patients with atopic hand eczema either showed 
complete or partial improvement. The results in the contact hand eczema group 
indicate that just 1 patient showed complete or partial remission of symptoms but it 
has to be noted that there were just 5 patients in this group.  
Just 20 out of the total 107 patients did not respond to the treatment.  
Interestingly, male patients responded better than female patients, which is in 
contrast to long-term follow-up studies. Perhaps male patients can avoid mechanical 
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irritation in acute situations, whereas female patients, even nowadays continue to 
perform house work (Meding et al. 2005), 
With the exception of erythema reaction in two patients, no side effects occurred and 
cream-PUVA therapy was well tolerated in all treated patients. 
A withdrawal rate of 15% of patients (16 patients) was observed. Treatment with 
cream-PUVA requires motivation and time. Patients have to be able to attend 
sessions up to four times per week and to apply the cream 1-2 hours beforehand. In 
our setting, a public health system with fixed office hours a variable scheduling of 
appointments is difficult. Increased and more flexible availability would reduce 
withdrawal rate significantly.  
 
Cream-PUVA photochemotherapy is an efficient regimen for the treatment of chronic 
recalcitrant hand eczema and offers a favourable safety profile regarding acute and 
long-term side effects. Comparison studies with new pharmacological substances 
such as alitretinoin have to be performed in the future. Combination of alitretinoin and 
cream-PUVA therapy might increase the efficacy and lower side effects. 
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Conclusion 
 
Several conclusions can be drawn from the above discussion.  
There seems to be a multitude of options available for the treatment of hand eczema 
and a large number of trials have been discussed. The problem is the low quality of 
the trials investigating this pathology.  
Looking at important study parameters leaves a total of three trials that fulfil the 
necessary criteria for randomized controlled double-blind trials. Practising evidence- 
based medicine means that treatment is based on results obtained in a rather small 
population of 1392 patients. The second major shortcoming is the lack of a standard 
comparator in the trials, which makes comparison of different treatment modalities 
very difficult and sometimes almost impossible. 
 
Adhering to the 22 CONSORT criteria (Moher et al. 2001) could help to eradicate all 
the inadequacies and problems discussed above. These criteria cover design, 
conduct and analysis of parallel-group randomized trials. In order to produce high 
quality randomized controlled studies trials need to have a clear randomization 
procedure with concealment of allocation, blinding of patients and investigators, 
intention-to-treat analysis, definition of rationale of sample size and major outcomes 
and an appropriate duration of treatment. A further imperative point is the definition of 
inclusion criteria and a clear diagnosis of the patients enrolled.  
Especially in the case of hand eczema it is vital to scrutinize the data according to 
subcategories of hand eczema. 
 
Due to the paucity of high quality randomized controlled trails in previous 
investigations, it is very difficult to make recommendations for a treatment algorithm 
of hand eczema. 
 
Of paramount importance is prevention of exposure to allergens, irritants and other 
exacerbating factors. Use of barrier creams if indicated can also make a big 
difference.  
Existing data also highlights the significance of regular use of bland emollients and 
topical corticosteroid. Most textbooks would employ these modalities as first line of 
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treatment for hand eczema. The majority of trials described above also allowed their 
participants to regularly use emollients, which underscores their importance. 
 
UV radiation therapy or alitretinoin treatment as second line after bland emollients 
and corticosteroid preparation seems to be a feasible option. Twelve trials with a 
patient population of 430 have been described above and reveal good efficacy. As 
discussed above, cream-PUVA photochemotherapy is an especially efficient regimen 
for the treatment of chronic recalcitrant hand eczema and offers a favourable safety 
profile regarding acute and long-term side effects. Treatment appears to be very 
efficacious in the subcategories of hyperkeratotic rhagadiform and dyshidrotic hand 
eczema. 
Outstanding data from high-quality trials gives evidence for and supports the use of 
retinoids or cyclosporine. In particular retinoid use in chronic hand eczema refractory 
to topical corticosteroids has been investigated in two large multicentre trials.  
Excellent data has been produced in the past to support use of radiotherapy as well. 
Due to the high side effect profile, predominantly teratogenicity and high carcinogenic 
potential, this and the other treatment modalities appear to be reserved for very 
severe and refractory cases and should be applied and looked after by a specialist 
centre. 
 
Fig 19 Treatment algorithm for hand eczema 
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High-quality comparison studies between standard therapies and new 
pharmacological substances such as alitretinoin and also combination therapies will 
enable us to further refine and advance this treatment algorithm. 
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